Probiotic supplementation increases fecal TLR4 agonists without improving disease activity in juvenile idiopathic arthritis: a randomized placebo-controlled trial
In brief
Probiotic raises gut TLR4 signals but does not improve JIA outcomes
In a double-blind trial of 44 children with oligoarticular or RF-negative polyarticular JIA, VSL#3 increased fecal Toll-like receptor 4 agonist activity but showed no clinical benefit-47% achieved an ACR Pedi 30 response versus 63% with placebo. Microbiota diversity and systemic inflammation were unchanged, suggesting probiotic use may not be effective in early-life autoimmune arthritis.
- Journal
- Gut microbes (Q1)
- Published
- 10 September 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Capucine Durand, Laurye-Anne Eveillard, Mathilde Labouret, Florence Aeschlimann, Alexandre Belot, Karine Brochard, et al.
- PMID
- 42720258
- DOI
- 10.1080/19490976.2026.2728351
Why clinicians should know about it
- Picked for Pediatrics and Child Health (top studies of the week, 13 September 2026): Not related to acute paediatric illnesses
- Picked for Gastroenterology (top studies of the week, 13 September 2026): Probiotic trial in juvenile idiopathic arthritis
- Picked for Microbiology (medical) (top studies of the week, 13 September 2026): Probiotic trial in juvenile idiopathic arthritis
Abstract
Gut dysbiosis has been implicated in the pathogenesis of juvenile idiopathic arthritis (JIA), suggesting that microbiota-targeted interventions may influence immune signalling during early immune development. We conducted the PERMAJI multicentre randomized, double-blind, placebo-controlled trial to evaluate the effects of probiotic supplementation (VSL#3) on host-microbiota immune interactions and disease activity in children with oligoarticular or RF-negative polyarticular JIA. Participants were randomly assigned (1:1) to receive VSL#3 or placebo for 3 months in addition to standard therapy. Stool and serum samples collected at baseline and month 3 were used to assess gut microbiota composition, fecal innate immune agonists, intestinal permeability, and systemic cytokines. The primary clinical endpoint was the proportion achieving an ACR Pedi 30 response at 3 months. Forty-four children were enrolled between September 2017 and July 2022. Clinical responses did not differ between groups (ACR Pedi 30: 47% with VSL#3 vs 63% with placebo; p = 0.33), and conservative worst-case assumptions for missing data suggested lower response rates with VSL#3 (36% vs 68%; p = 0.03). Probiotic supplementation significantly increased fecal Toll-like receptor 4 (TLR4) agonist activity, whereas gut microbiota diversity, intestinal permeability, and systemic cytokine levels remained unchanged. These findings indicate that probiotic supplementation can modify microbial innate immune signalling without detectable changes in microbial community diversity and may increase exposure to pro-inflammatory microbial stimuli in early-life autoimmune disease. The results highlight the complexity of host-microbiota immune interactions and underscore the need for careful evaluation of microbiome-targeted therapies in paediatric autoimmune disorders.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.